Diabetes Research Institute Foundation Congratulates Dr. Jay Skyler on Appointment to SAB Biotherapeutics’ Board of Directors

The Diabetes Research Institute Foundation (DRIF) extends its heartfelt congratulations to Dr. Jay Skyler on his recent appointment to the Board of Directors at SAB Biotherapeutics (Nasdaq: SABS). This appointment marks a significant achievement for both Dr. Skyler and the ongoing mission at the Diabetes Research Institute (DRI).

Dr. Skyler’s extensive expertise and leadership in type 1 diabetes research make him an invaluable addition to SAB’s board. His decades-long commitment to advancing our understanding of T1D, coupled with his vision for innovative therapies, align perfectly with SAB’s mission to develop a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of this chronic condition.

Commenting on his appointment, Dr. Skyler expressed optimism about the potential of SAB’s novel approach with SAB-142 to contribute to delaying the onset or progression of T1D. He emphasized the importance of disease modification in achieving therapeutic goals, a sentiment that resonates deeply with the Diabetes Research Institute Foundation’s mission.

Dr. Skyler’s distinguished career in diabetes research spans over five decades, during which he has held various leadership roles, including Director of the Division of Endocrinology Diabetes & Metabolism at the University of Miami Leonard M. Miller School of Medicine. His contributions to landmark clinical trials, such as the NIH (NIDDK)-sponsored Diabetes Prevention Trial – Type 1 (DPT-1) and Type 1 Diabetes TrialNet, have significantly advanced our understanding of T1D and paved the way for innovative treatments.

As Deputy Director for Clinical Research and Academic Programs at the Diabetes Research Institute, University of Miami, Dr. Skyler continues to drive progress in diabetes research and treatment. His appointment to SAB’s Board of Directors further underscores his dedication to advancing therapies that can positively impact the lives of individuals living with T1D.

The Diabetes Research Institute Foundation congratulates Dr. Skyler on this well-deserved appointment and looks forward to his ongoing leadership in the fight against type 1 diabetes.

About the Diabetes Research Institute (DRI) and Foundation

The Diabetes Research Institute (DRI) and Foundation were created for one reason – to cure diabetes – which is and will continue to be the singular focus until that goal is reached. As one of the largest and most comprehensive research centers dedicated to curing diabetes, the DRI is working to restore natural insulin production and normalize blood sugar levels without imposing other risks. Researchers have already shown that transplanted insulin-producing islet cells allow people with type 1 diabetes to live without the need for insulin injections. Some of the DRI’s islet transplant patients have been free from insulin for more than 10 years. Funding provided by the Foundation is the driving force that allows DRI scientists to pursue new and innovative ideas, and to speed these discoveries to patients. The Diabetes Research Institute Foundation is the organization of choice for those who want to Be Part of the Cure. For more information, please visit or call 800-321-3437.

Keep Up With Our Progress Toward A Cure & More